King has more than 20 years of senior, global, commercial leadership experience within the biotechnology rare disease space, most recently with Alexion Pharmaceuticals.
At Alexion Pharmaceuticals, he served most recently as vice president, US neurology business unit. He also served as vice president, head of global LAL-D Franchise and vice president, head of global PNH Franchise.
Prior to joining Alexion in 2009, King served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals. He began his career at Ernst and Young LLP.
King obtained his BS in business logistics and labor relations and his MBA in finance and management from Pennsylvania State University.
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The company discovers and develops peptides and small molecules to target key components of the complement cascade.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer